Neither cancer nor myositis are common in patients testing positive for anti-TIF1γ by line blot in real-world laboratory settings

被引：2
|
作者：
Troelnikov, Alexander [1 ,2 ,5 ]
Choo, Xin Jing [3 ]
Beroukas, Dimitra [1 ,2 ]
Limaye, Vidya [3 ,4 ]
机构：
[1] Immunopathol Dept, SA Pathol, Adelaide, SA, Australia
[2] Flinders Univ S Australia, Adelaide, SA, Australia
[3] Univ Adelaide, Discipline Med, Adelaide, SA, Australia
[4] Royal Adelaide Hosp, Rheumatol Dept, Adelaide, SA, Australia
[5] Immunol Dept, SA Pathol, Level 3,Frome Rd, Adelaide, SA 5000, Australia
来源：
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | 2023年 / 26卷 / 03期
关键词：
AUTOANTIBODIES;
D O I：
10.1111/1756-185X.14552
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：586 / 590
页数：5
相关论文
共 50 条
  • [1] NEITHER CANCER NOR MYOSITIS ARE COMMON IN PATIENTS TESTING POSITIVE FOR TIF1. BY LINE IMMUNOBLOT ASSAY
    Troelnikov, Alexander
    Choo, Xin Jing
    Beroukas, Dimi
    Limaye, Vidya
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 455 - 455
  • [2] A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing
    Mulhearn, Ben
    Li, Danyang
    McMorrow, Fionnuala
    Lu, Hui
    McHugh, Neil J.
    Tansley, Sarah L.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [3] Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies
    Nhung Thi My Ly
    Ma, Ni
    Ueda-Hayakawa, Ikuko
    Chuyen Thi Hong Nguyen
    Anada, Reiko
    Okamoto, Hiroyuki
    Fujimoto, Manabu
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2021, 104 (03) : 177 - 184
  • [4] Machine Learning Algorithms Identify Clinical Subtypes and Cancer in Anti-TIF1γ+ Myositis: A Longitudinal Study of 87 Patients
    Zhao, Lijuan
    Xie, Shuoshan
    Zhou, Bin
    Shen, Chuyu
    Li, Liya
    Pi, Weiwei
    Gong, Zhen
    Zhao, Jing
    Peng, Qi
    Zhou, Junyu
    Peng, Jiaqi
    Zhou, Yan
    Zou, Lingxiao
    Song, Liang
    Zhu, Honglin
    Luo, Hui
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [5] Anti-Sp4 and anti-CCAR1 autoantibodies in UK vs US patients with adult and juvenile-onset anti-TIF1γ-positive myositis
    McMorrow, Fionnuala K.
    Wedderburn, Lucy R.
    Chinoy, Hector
    Oldroyd, Alexander
    Lamb, Janine A.
    Rider, Lisa G.
    Mammen, Andrew L.
    Casciola-Rosen, Livia
    McHugh, Neil J.
    Tansley, Sarah L.
    RHEUMATOLOGY, 2024,
  • [6] Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies (vol 104, pg 177, 2021)
    Ly, Nhung Thi My
    Ma, Ni
    Ueda-Hayakawa, Ikuko
    Nguyen, Chuyen Thi Hong
    Anada, Reiko
    Okamoto, Hiroyuki
    Fujimoto, Manabu
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2022, 107 (01) : 56 - 56
  • [7] TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1γ positive cancer-associated dermatomyositis
    Cordel, Nadege
    Derambure, Celine
    Coutant, Sophie
    Mariette, Xavier
    Jullien, Denis
    Debarbieux, Sebastien
    Chosidow, Olivier
    Meyer, Alain
    Bessis, Didier
    Joly, Pascal
    Mathian, Alexis
    Levesque, Herve
    Sabourin, Jean-Christophe
    Tournier, Isabelle
    Boyer, Olivier
    RHEUMATOLOGY, 2021, 60 (12) : 5863 - 5867
  • [8] Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings
    Amit Kumar
    Akhil Kapoor
    Vanita Noronha
    Vijay Patil
    Nandini Menon
    Ajay Kumar Singh
    Amit Joshi
    Amit Janu
    Rajiv Kumar Kaushal
    Trupti Pai
    Anuradha Chougule
    Omshree Shetty
    Kumar Prabhash
    BJC Reports, 2 (1):
  • [9] Analysis of Real-World PD-L1 Testing for Clinical Use in Patients with Lung Cancer
    Krigsfeld, G. S.
    Zerba, K.
    Chizhevsky, V.
    Ragheb, J. W.
    White, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (01): : 236 - 236
  • [10] Clinical Outcomes of Crizotinib in Real-World Practice Settings for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer
    Davis, K. L.
    Lenz, C.
    Houghton, K.
    Kaye, J. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 238 - 239
12345